Development of a multiparameter flow cytometric assay as a potential biomarker for homologous recombination deficiency in women with high-grade serous ovarian cancer by Jung-Min Lee et al.
Lee et al. J Transl Med  (2015) 13:239 
DOI 10.1186/s12967-015-0604-z
RESEARCH
Development of a multiparameter 
flow cytometric assay as a potential biomarker 
for homologous recombination deficiency 
in women with high-grade serous ovarian 
cancer
Jung‑Min Lee1*†, Nicolas Gordon1†, Jane B Trepel2, Min‑Jung Lee2, Minshu Yu1 and Elise C Kohn1
Abstract 
Objectives: PARP inhibitors (PARPi) are a novel class of drugs with activity in patients with acquired or germline 
homologous recombination (HR) deficiency‑associated high‑grade serous ovarian cancer (HGSOC). We hypothesized 
that measuring γH2AX as an indicator of DNA double‑strand breaks (DSB), and MRE11 or RAD51 as an indicator of 
DSB repair, would reflect HR status and predict response to PARPi‑based therapy. Our aim was to develop and use 
high‑throughput multiparametric flow cytometry to quantify γH2AX with MRE11 or RAD51 in PBMCs as a readily 
available surrogate.
Methods: Healthy donor PBMCs were used for assay development and optimization. We validated induction of 
γH2AX, MRE11 and RAD51 by staining with fluorophore‑conjugated antibodies. The multiparameter flow cytometric 
method was applied to PBMC samples from recurrent HGSOC patients who were treated with PARPi, olaparib and 
carboplatin.
Results: Stimulation was necessary for quantification of a DNA damage response to olaparib/carboplatin in healthy 
donor PBMCs. The flow cytometric protocol could not distinguish between cytoplasmic and nuclear RAD51, errone‑
ously indicating activation in response to injury. Thus, MRE11 was selected as the marker of DSB repair. PBMCs from 
15 recurrent HGSOC patients were then examined. Patients who did not respond to PARPi therapy had a significantly 
higher pre‑treatment level of γH2AX (p = 0.01), and a higher ratio of γH2AX/MRE11 (11.0 [3.5–13.2] v. 3.3 [2.8–9.9], 
p < 0.03) compared with responders.
Conclusions: We successfully developed and applied a multiparameter flow cytometry assay to measure γH2AX and 
MRE11 in PBMCs. Prospective studies will be required to validate this surrogate biomarker assay as a potential predic‑
tive biomarker of PARPi‑based therapy.
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Background
Poly(ADP-ribose) polymerase inhibitors (PARPi) are a 
novel class of drugs with promising activity in patients 
with deleterious germline BRCA1 and BRCA2 mutation 
(gBRCAm)-associated ovarian and breast cancers, and 
sporadic high-grade serous ovarian cancer (HGSOC) 
[1, 2]. The PARPi, olaparib was recently approved by US 
Food and Drug Administration for heavily pretreated 
gBRCAm-associated ovarian cancer. Reported response 
rates (RRs) are ~40% in gBRCAm and 24% in BRCA1/2 
wild-type (BRCAwt) ovarian cancer patients [1]. The 
susceptibility of patients with gBRCAm-associated ovar-
ian cancer to DNA damaging agents, including PARPi, 
has validated gBRCAm as a predictive biomarker for 
PARPi response [3]. However, at least half of gBRCAm 
biomarker-positive women do not respond well to PARPi 
and many BRCAwt HGSOC women do respond. The 
challenge remains to identify, develop, and validate bio-
markers to apply within this HGSOC patient population 
to predict more accurately who will benefit from PARPi 
therapies.
One of the key components in DNA damage repair is 
the histone protein H2AX, which becomes rapidly phos-
phorylated on serine 139 to form γH2AX, a process 
occurring at nascent DNA double-strand breaks (DSBs) 
[4]. This creates a focus for accumulation of DNA repair 
and chromatin remodeling proteins. γH2AX has been 
proposed as a biomarker of DSBs in response to dam-
age. These DSBs can be immunolabeled with an anti-
body to 139Ser-phosphorylated H2AX, and the extent 
of DSBs estimated from the number of labeled nuclear 
foci or by measuring overall γH2AX protein levels [4]. 
Accumulation of γH2AX forms an injury protein/DNA 
complex that recruits repair proteins, including MRE11 
and RAD51 [5, 6]. MRE11 binds to the damaged DNA 
and subsequently recruits and activates additional pro-
teins including BRCA1, BRCA2, and RAD51 to activate 
the repair process [7]. RAD51 forms quantifiable nuclear 
immunofluorescence-detectable foci that represent the 
repair protein complex assembly at sites of homologous 
recombination (HR) [8].
There is precedent for examination of γH2AX, RAD51 
and MRE11 as potential biomarkers of HR competence. 
γH2AX has been used as a pharmacodynamic biomarker 
of DNA damaging agents, measured in surrogate tissues 
such as plucked eyebrow-hair follicles, peripheral blood 
mononuclear cells (PBMCs), and has also been examined 
in tumor cells [9–11]. RAD51 focus formation was used 
to assess HR competence in HGSOC ascites primary 
cultures and correlated with response to PARPi in vitro 
[12]. MRE11 protein expression by immunohistochemis-
try was shown to correlate with disease-specific survival 
in localized invasive bladder cancer patients receiving 
radiotherapy [13, 14]. However, none of these are vali-
dated as a biomarker to predict clinical drug benefit, and 
it is possible that neither measures of damage nor meas-
ures of repair are sufficient in isolation.
PBMCs from cancer patients have been investigated 
as readily available surrogate sources in which to exam-
ine pharmacodynamic responses [15–17]. PBMCs from 
breast and lung cancer patients yielded greater in  vitro 
accumulation of DNA damage after radiation measured 
by micronucleus-centromere and comet assays com-
pared to healthy donor PBMCs, possibly reflecting tumor 
genomic instability and indicating PBMCs can serve as a 
surrogate tumor [17–19]. Our aim was to quantify DNA 
damage and repair in PBMCs from HGSOC patients 
using a rapid, high-throughput quantitative measure, 
such as flow cytometry, that could be applicable broadly. 
We hypothesized that a gauge incorporating both DNA 
damage and repair may more accurately characterize sus-
ceptibility to PARPi-based therapy. Here, we demonstrate 
the development and application of a multiparameter 
flow cytometric method measuring γH2AX and MRE11 
in PBMCs from women with HGSOC who received 
PARPi therapy.
Methods
Healthy donor PBMC collection, isolation, stimulation, 
and treatment
PBMCs from healthy donors were obtained from the 
NIH Clinical Center Department of Transfusion Medi-
cine under their Institutional Review Board (IRB)-
approved and consented healthy donor program. PBMCs 
were spun in cell separation tubes for 30 min at 1,500×g 
within 2 h of venipuncture, and isolated cells were incu-
bated overnight in serum-containing medium. Viabil-
ity was determined by trypan blue exclusion prior to 
use. Where indicated, phorbol myristate acetate (PMA, 
50  ng/mL) and ionomycin (1 μg/mL) or DMSO vehicle 
control (<0.05%) were added to stimulate donor PBMCs 
for 4  h before treatment with carboplatin 50  μM and 
olaparib 10 μM (Selleck Chemicals, Houston, TX, USA) 
or DMSO (<0.05%). Where indicated donor PBMCs 
were frozen in medium containing 90% FBS/10% DMSO 
and placed at −80°C overnight, with a parallel set desig-
nated for flow cytometry without first freezing. Frozen 
cells were thawed at room temperature, washed once in 
PBS, and seeded onto 24-well plates in serum-contain-
ing RPMI-1640 medium. Paired freeze/thaw and direct 
stained PBMC sets were from the same donor.
Flow cytometry
A standard validated intracellular staining protocol was 
used [20]. PBMCs were fixed overnight in 0.4% para-
formaldehyde at 4°C and subsequently stained. Primary 
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antibodies for single-color flow cytometry included rab-
bit anti human-γH2AX preconjugated with Alexa Fluor 
488 (1:200; Abcam, Cambridge, MA, USA), rabbit anti-
human MRE11 (1:100; Cell Signaling Technology, Bev-
erly, MA, USA), and rabbit anti-human RAD51A (1:100; 
Abcam). Alexa Fluor 488 conjugated goat anti-rabbit IgG 
(1:500; Invitrogen, Grand Island, NY, USA) was used as a 
secondary antibody for MRE11 and RAD51. The single-
color flow protocol was used during experiments to opti-
mize the stimulation conditions, after which a dual-stain 
protocol was optimized using antibodies from different 
species: rabbit anti-human RAD51A (1:100; Abcam) and 
mouse anti-human γH2AX (1:200; Abcam), and rabbit 
anti-human MRE11 (1:100; Cell Signaling Technology). 
Alexa Fluor 488 goat anti-rabbit IgG was used as the sec-
ondary antibody for MRE11 and RAD51. Alexa Fluor 647 
goat anti-mouse IgG (1:500; Abcam) was the secondary 
antibody for γH2AX. Negative controls of dual-stain flow 
cytometry used anti-rabbit IgG isotype (Cell Signaling) 
and anti-mouse IgG isotype controls (Abcam) at the same 
dilutions as the associated primary antibodies. Unstained 
cells were subjected to the same treatments and detec-
tion methods as stained cells without the use of primary 
or secondary antibodies. PBMCs were examined using a 
MACSQuant Analyzer (Miltenyi Biotec; Bergisch Glad-
bach, DE, USA) and the median fluorescence intensity 
(MFI) determined by FlowJo v.X.0.6 (Treestar; Ashland, 
OR, USA) as reported [20]. All data for the development 
assays are the result of three independent experiments 
and are presented as mean ± SEM. Patient samples were 
analyzed once with a minimum of 10,000 viable cells 
examined per data point. Dead cells were excluded using 
the LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Life 
Technologies; Carlsbad, CA, USA).
Immunofluorescence confocal microscopy (IF)
Healthy donor PBMCs designated for IF were treated 
in parallel with those designated for flow cytometry 
throughout stimulation and drug exposure. Cells were 
cytospun onto silylated slides (CEL Associates; Pearl-
and, TX, USA) and were stained with mouse anti-human 
γH2AX (1:200, Abcam) and rabbit anti-MRE11 (1:200, 
Abcam), and rabbit anti-RAD51 (1:50, Santa Cruz Bio-
technology; Santa Cruz, CA, USA) using our standard 
laboratory immunofluorescence protocol [21]. Alexa 
Fluor 488 goat-anti mouse IgG and Alexa Fluor 488 goat-
anti rabbit IgG (1:500, Invitrogen) were used for IF detec-
tion. The slides were mounted with Vectashield mounting 
medium with DAPI (Vector Labs; Burlingame, CA, USA) 
and images were collected as Z stacks using a Zeiss LSM 
780 confocal microscope at 1000× magnification. Images 
were analyzed using Zeiss LSM Image Browser version 
4.2.0.121 software.
Patients and samples
We applied the multiparameter flow cytometric method 
to PBMC samples from patients with recurrent HGSOC 
who were enrolled on one of two phase I studies con-
ducted at the Center for Cancer Research, NCI; treatment 
and use of the PBMCs for this purpose was approved by 
the NCI IRB, and all patients had provided informed 
consent for such use. Patients received olaparib capsules 
400 mg every 12 h (days 1–7) and carboplatin AUC4 or 
5 every 21 days (NCT01445418) [22], or olaparib tablets 
200  mg every 12  h (days 1–7) with carboplatin AUC4 
every 21  days (NCT01237067). No more than eight 
combination cycles were given, and all non-progressing 
patients continued on twice-daily olaparib maintenance 
therapy until disease progression. Tumor response was 
assessed by imaging and physical exam every two cycles 
using Response Evaluation Criteria in Solid Tumors cri-
teria. PBMCs were collected prior to treatment initiation 
and stored viably frozen at −80°C until use.
Statistics
Data for the development assays were log transformed 
and subjected to the two-way analysis of variance. The 
Shapiro–Wilk test was used to test for normality after 
each ANOVA. The ability of the pre-treatment individual 
markers, measured by flow cytometry, to predict clini-
cal response was evaluated by the Mann–Whitney test. 
All statistical analyses were 2-sided and performed with 
GraphPad Prism version 6.0 (GraphPad Software; La 
Jolla, CA, USA).
Results
PBMC stimulation is necessary for DNA damage 
accumulation in healthy donor PBMCs
The use of healthy volunteer PBMCs as a surrogate 
resource for biomarker development and application 
required demonstration that they could acquire DNA 
damage. We thus began by modeling the treatment 
effect of olaparib/carboplatin (O/C) on the expression of 
γH2AX, MRE11, and RAD51 in healthy donor PBMCs. 
Figure  1a shows no induction of γH2AX, MRE11, or 
RAD51 expression after exposure to O/C at physiologi-
cally attainable concentrations for 48  h. Expression of 
the three proteins was induced in response to O/C only 
when PBMCs were stimulated with PMA/I (Figure  1b–
d). Three conditions of stimulation were examined. In the 
first, PBMCs were stimulated with PMA/I, washed and 
then exposed to O/C for 48 h; the second introduced O/C 
at 4 h for 24 h, then cells were washed and re-exposed to 
O/C for an additional 24 h; the third introduced O/C for 
48 h after the initial 4 h stimulation with no washouts. All 
three conditions induced statistically significant changes 
in γH2AX, MRE11 and RAD51 expression after 24 h (all 
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p < 0.001). Notably, stimulation for 4 h followed by wash-
out and subsequent O/C treatment for up to 48 h (condi-
tion  1) yielded a greater expression of γH2AX, MRE11, 
and RAD51 after 48 h treatment compared to the other 
two conditions. Flow cytometry secondary antibody and 
fluorophore negative controls showed no significant sig-
nal (data not shown).
Freezing and thawing affects the number of viable cells, 
but not protein expression
In clinical trial settings, PBMCs are collected from 
patients over time after which they are, optimally, exam-
ined in a batched setting. Hence, we examined the pre-
analytical effect of the freeze/thaw cycle on the cell 
viability and flow outcome using paired PBMC samples. 
Paired samples from the same patient were subjected 
to a freeze/thaw cycle or held on wet ice, then both sets 
were subjected to immediate fixation and staining. Single 
label staining was used and dead cells were excluded and 
used to determine % viability as per “Methods”. There was 
no statistically significant change in protein expression 
between fresh and frozen samples from two independ-
ent experiments (Additional file  1: Figure  S1A). There 
was an approximately 25% reduction in the number of 
viable cells obtained from frozen samples compared to 
fresh samples (p = 0.048; Additional file 1: Figure S1B). 
We concluded that using frozen patient samples would 
require a higher cell count and necessitate the use of a 
viability dye, but should not affect reliable measurable 
protein expression determined by flow cytometry.
Optimization of multiparameter flow cytometry
Use of a multiparameter flow cytometry procedure would 
minimize introduction of experimental bias and allow 
endpoint analysis with a fewer net number of patient 
PBMCs. We optimized a multiparameter flow cytom-
etry procedure and applied it to examine the pattern of 
expression of γH2AX with MRE11, or with RAD51 in 
response to O/C treatment. Induction of MRE11 expres-
sion was delayed and significantly increased compared to 
stimulated, but untreated controls after 24 h of treatment, 
and compared to γH2AX after 48  h of treatment (all 
p < 0.002; Figure 1e). γH2AX expression increased pro-
gressively over time (all p < 0.02; Figure 1e). Both RAD51 
and γH2AX showed a significant increase in expression 
compared to stimulated, but untreated controls after 12 h 
(all p < 0.002), and RAD51 was significantly higher than 
γH2AX after 24  h (all p  <  0.002). Multiparameter flow 
cytometry allowed simultaneous evaluation of measures 
of DNA injury and repair.
Demonstration of induction of γH2AX and MRE11 by IF
Immunofluorescence was used to both confirm the tem-
poral and qualitative induction of the signals for γH2AX, 
RAD51, and MRE11, and also to evaluate the subcellular 
localization of the IF signal for evaluation of off-target 
non-nuclear staining that could bias the flow cytomet-
ric interpretation. Figure  2 shows representative pan-
els of single stain IF confocal images obtained over the 
same treatment time course as replicate multiparameter 
flow cytometric studies. γH2AX and MRE11 (Figure 2a, 
b) stained nuclear foci, and focus formation increased 
progressively over injury time. RAD51 foci were both 
nuclear and cytoplasmic (Figure  2c, arrowheads). Few 
nuclear RAD51 foci were visible at 12 and 24  h, with 
discreet perinuclear cytoplasmic foci seen at 24 h, peak-
ing at 36  h. By 48  h, all RAD51 was nuclear. The flow 
cytometric protocol used cannot distinguish between 
cytoplasmic and nuclear RAD51 and interpretation of 
RAD51 results would erroneously include cytoplasmic 
RAD51 staining as activation in response to injury in a 
clinical setting where there may not be control for expo-
sure time that this experiment suggests to be necessary. 
Thus, MRE11 was selected as the marker of DSB repair 
for analysis of patient PBMCs by multiparameter flow 
cytometry.
De novo production of MRE11 occurs in response 
to treatment with olaparib/carboplatin
MRE11 is the repair protein recruited in response to 
DNA injury. The delay in expression of MRE11 detected 
by flow cytometry seen in Figure 1e raised the possibil-
ity of the need for de novo production of MRE11 upon 
DNA DSB. Cycloheximide (100 μM) was used to block 
de novo protein synthesis. This concentration inhibits 
lymphocyte protein synthesis up to 92% with a minimal 
induction of apoptosis [23]. Figure  3a shows no induc-
tion of MRE11 in cells pre-treated with PMA/I in the 
(See figure on previous page.)
Figure 1 Optimization of PBMC flow cytometry method. a Unstimulated PBMCs. Cells were seeded and incubated overnight without PMA/I stimu‑
lation before treatment with olaparib/carboplatin (O/C) for 48 h. b–d Optimization of stimulation conditions. Condition 1: PMA/I × 4 h followed by 
PBS washout and subsequent O/C × 48 h (P/I × 4 h > O/C × 48 h); condition 2: PMA/I × 4 h then O/C × 24 h followed by washout and subsequent 
O/C × 24 h (P/I × 4 h–O/C × 24 h > O/C × 24 h); condition 3: PMA/I × 4 h followed by O/C × 48 h with no washout (P/I × 4 h–O/C × 48 h).  
Cells were collected after 24, 36 and 48 h of treatment before undergoing the single‑stain flow cytometry protocol. b γH2AX; c MRE11; d RAD51.  
e, f Demonstration of optimized dual‑stain. Cells were plated and treated according to condition 1 before undergoing the dual‑stain process for 
MRE11 and γH2AX (e), or for RAD51 and γH2AX (f).
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presence of cycloheximide for 4 h prior to treatment with 
O/C. Cycloheximide did not have a significant effect on 
the expression of γH2AX over the same time interval, 
consistent with the fact that γH2AX arises as the result 
of post-translational modification and should there-
fore be unaffected by the inhibition of protein synthesis 
Figure 2 Demonstration of target proteins by IF confocal microscopy. Cells were collected prior to stimulation with PMA/I (−4 h), after stimulation 
but prior to treatment with O/C (0 h) and every 12 h afterwards for 48 h. a γH2AX; b MRE11; c RAD51.
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(Figure  3b). These results indicate that induction of 
MRE11 protein is a result of exposure to DNA damaging 
agents and is measurable in stimulated PBMCs.
Patients who do not respond to PARPi‑based therapy 
have significantly higher baseline levels of γH2AX 
and MRE11, and a higher ratio of γH2AX/MRE11 compared 
with responders
We applied our multiparameter flow cytometric γH2AX/
MRE11 assay to archival PBMC samples from 15 patients 
with recurrent HGSOC who received the PARPi, olapa-
rib and carboplatin [22]. Tables  1 and 2 summarize the 
characteristics and clinical responses of this subset of 
patients. The global distribution of γH2AX and MRE11 
expression across all the patients is shown in Figure 4a, 
b. In this small group, patients whose best response was 
stable disease or progression expressed higher pre-treat-
ment levels of both γH2AX and MRE11 compared to 
patients who had complete or partial responses (p = 0.01 
and p =  0.11; Figure 4c, d). We proposed that the ratio 
Figure 3 De novo production of MRE11 in response to DNA damage. a Cycloheximide (CHM) abolishes MRE11 response to O/C injury. b CHM 
does not inhibit the expression of γH2AX. 24 and 48 h time points compared to 0 time point, and comparison of O/C treatment only (O/C) to CHM 
followed by O/C (CHM > O/C) for MRE11 or γH2AX at the same time point.





Age in years, median (range) 61 (41–73) 49 (35–57)
Platinum sensitive/platinum‑resistant recurrent ovarian cancer,  
number of patients
3/7 4/1
Number of prior regimens, median (range) 7 (4–12) 5 (4–8)
Table 2 Clinical response
Best response HGSOC with gBRCAm HGSOC without gBRCAm Total (N)
Median duration of response (range) Median duration of response (range)
CR 0 0 0
PR 5/5 (100%)




SD ≥ 4 months 0/5 3/10
4 months (4–5 months)
3/15 (20%)
PD 0/5 6/10 (60%) 6/15 (40%)
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of the values of injury to repair, γH2AX/MRE11, may 
provide a better view of the DNA repair status in the 
patient PBMCs. The median value of the γH2AX/MRE11 
ratio of non-responders was significantly higher com-
pared to responders, indicating more injury than repair 
(11.0 [range 3.5–13.2] v. 3.3 [range 2.8–9.9], p =  0.026; 
Figure 4e). Figures 4f–h show the distribution of γH2AX 
and MRE11 expression and ratio of γH2AX/MRE11 
in patients as a function of gBRCAm status. Five of the 
15 patients were gBRCAm carriers, and showed signifi-
cantly lower pre-treatment levels of both γH2AX and 
MRE11 compared to non-mutation carriers (all p < 0.017; 
Figure  4f, g). The median value of the γH2AX/MRE11 
ratio of BRCAwt was significantly higher compared to 
gBRCAm carriers (10.5 [range 3.5–13.2] v. 2.9 [range 
2.8–8.4], p < 0.01; Figure 4h).
Discussion
The development of rapidly testable and analytically 
reliable biomarkers to predict susceptibility to agents 
targeting HR deficiency is necessary to guide optimal 
application of PARPi. We hypothesized that quantifi-
cation of DNA damage and repair using γH2AX and 
MRE11 or RAD51 may more accurately measure HR 
potential. We demonstrate the successful development 
of a multiparameter flow cytometry assay to measure HR 
status and applied it to a test set of PBMCs from recur-
rent HGSOC patients receiving a PARPi treatment regi-
men in a pilot evaluation. Our findings show that patients 
who do not respond to PARPi-based therapy have signifi-
cantly higher pretreatment levels of γH2AX and MRE11 
and the higher ratio of γH2AX/MRE11, which was 
opposite of what we expected. We anticipated that non-
responders would have the lower ratio of γH2AX/MRE11 
due to increased repair function. It is possible that the 
presence of both underlying DNA damage and increased 
repair activity are likely due to their prior exposure to 
DNA damaging agents and other cytotoxic chemothera-
pies prior to study enrollment and our results suggest 
greater baseline injury than repair may reflect a potential 
mechanism of resistance.
Approximately 50% of HGSOC tumors are proposed to 
have some deficiency in HR, due to gBRCAm or acquired 
defects in proteins of the HR pathway [24]. RAD51 is 
a DNA recombinase that interacts with BRCA2 and 
other HR proteins upon DNA injury [25]. DNA DSB are 
resected to generate single stranded (ss) DNA tails and 
the RAD51-ssDNA filaments continue to grow from 
a BRCA2-stablized filament nucleus to form an ATP-
bound nucleoprotein filament, capable of homologous 
DNA pairing [26]. Quantification of RAD51 nuclear 
focus formation has been used to assess HR compe-
tence in epithelial ovarian cancer ascites primary cul-
tures, and was correlated with response to PARPi in vitro 
[12]. Dedes et  al. demonstrated a correlation between 
reduced RAD51 nuclear focus formation and PARPi sen-
sitivity in PTEN-deficient endometrial cancer cell lines in 
in vitro [27]. Low quantities of RAD51 foci measured by 
IF in post-chemotherapy biopsies were associated with 
pathologic complete response to anthracycline-based 
chemotherapy in sporadic primary breast cancers [28]. 
However, none of these studies examined if the pres-
ence of RAD51 foci prior to or early in therapy could 
predict clinical benefit. None used a method that could 
be applied readily in a more high throughput fashion. 
While our findings showed RAD51 could be measured by 
flow cytometry and reflected injury, our confirmation of 
concomitant cytosolic expression during the time frame 
of injury indicates that a flow cytometry method would 
erroneously count cytoplasmic RAD51 staining as posi-
tive for repair in response to injury. Therefore, any meas-
ure of RAD51 as a predictive biomarker would need to 
control for subcellular localization as a function of time.
MRE11 is a nuclease that facilitates the generation of 
3′ overhangs by making a DNA nick at a point separate 
from the break ends, creating an entry site for further 
processing by exonuclease enzymes [29–31]. The 5′-ter-
minated DNA strand must first be resected to gener-
ate a 3′ single-stranded DNA overhang for repair by HR 
[31]. The MRE11/RAD50/NBS1 (MRN) complex binds 
tightly to chromatin in the absence of DNA damage dur-
ing S phase [32]. HR is activated and works during the S 
and G2 phases of the cell cycle [33]. Martin et al. showed 
MRE11 is induced in response to DNA injury and co-
localized with γH2AX after irradiation, measured by IF in 
lymphoblastoid cell lines in vitro [34]. Choudhry and col-
leagues examined protein expression of MRE11, RAD50, 
NBS1, ATM, and H2AX by immunohistochemistry in 
(See figure on previous page.)
Figure 4 Injury and repair surrogates trend with outcome in PBMCs from women treated with O/C. PBMCs obtained from 15 women pretreated 
with O/C and viably frozen were available and analyzed according to our demonstrated SOP. The graphed values in y axis are raw MFI levels as they 
represent data from patient samples taken at only one time point (before O/C treatment). a γH2AX; b MRE11. Median MFI levels of γH2AX (c) and 
MRE11 (d) were lower in patients with objective measurable responses to O/C. A pretreatment ratio of γH2AX/MRE11 was significantly higher in 
patients with no measurable response to O/C (e). Pre‑treatment γH2AX (f), MRE11 (g) and a ratio of γH2AX/MRE11 (h) by dual‑label flow cytometry 
are lower in gBRCAm patients compared with BRCAwt patients.
Page 10 of 12Lee et al. J Transl Med  (2015) 13:239 
pretreatment tumor specimens from 179 bladder cancer 
patients receiving radical radiotherapy. They showed low 
MRE11 protein expression was associated with worse 
cancer-specific survival following radiotherapy [14]. We 
confirm that MRE11 is a preferable measure of DNA DSB 
repair in a flow cytometry high throughput approach, as 
it is selectively nuclear. Our finding of cycloheximide-
sensitive induction of MRE11 indicates that in this model 
system, new MRE11 protein is induced secondary to cel-
lular recognition of DNA injury. This further suggests 
that MRE11 may be a more useful marker, as it is respon-
sive to dynamic cellular events. It has been reported that 
MRE11 recruitment at the sites of DNA damage is rapid 
and detectable by IF within 10–20  min after irradiation 
in human fibroblasts [35–37]. A small subset of HR defi-
cient cancers have been found to have MRE11 mutations 
providing a rare confounder while supporting the poten-
tial of low MRE11 as a biomarker of HR behavior [38, 39].
Flow cytometry offers the possibility to quantify 
γH2AX or MRE11 expression in large cell populations 
[40, 41]. The flow cytometric approach to measure DNA 
damage is rapid, more sensitive, and less cumbersome 
compared with alternative, commonly used methods, 
including the comet assay for single cell DNA damage 
assessment or IF analysis of γH2AX or MRE11 nuclear 
foci [42, 43]. The use of dual staining may have resulted in 
a reduction in dynamic range in the flow cytometry assay. 
This may be due to use of different antibodies and detec-
tion reagents. The flow cytometric assay reported here 
requires only 2 mL of whole blood and can be performed 
with as few as 105 PBMCs [42]. In a study by Wilkins 
et al., flow cytometric analysis of the level of γH2AX in 
PBMCs was examined in prostate cancer patients as a 
potential marker of radiosensitivity, which was defined 
by radiation therapy-induced proctitis. That study which 
looked at γH2AX alone found no correlations of γH2AX 
expression by flow cytometry and radiation sensitivity 
[44]. Our pilot study shows that both DNA injury and 
repair can be measured and correlated in single cells by 
high-throughput flow cytometry.
Preanalytical variables are important in biomarker 
reliability. It is possible that there may be false positive 
γH2AX or MRE11 staining due to cell injury caused 
during PBMC freezing and storage. Our findings indi-
cate that the freezing and thawing process affected cell 
viability, but did not result in a significant differences 
in expression of γH2AX, MRE11 or RAD51 compared 
to paired fresh samples. In addition, the flow cytometry 
assay includes two approaches to gating out dead cells to 
overcome this issue. Light scatter properties and use of 
the LIVE/DEAD Fixable Aqua dead cell stain allow confi-
dence in target measurements in live cells.
Our study has some limitations. First, a small patient 
sample size may introduce biases in interpreting the 
relationship between the flow cytometry results and 
clinical responses. Second, this post hoc study of 15 
patients was an exploratory objective, and the study 
sample size was not powered to address this question, 
thus it is possible that a dual-label flow cytometry assay 
may not predict the clinical response. Third, it should 
be stressed that despite our findings related to the sen-
sitivity to PARPi based therapy, the majority of respond-
ers were gBRCAm carriers and all patients were heavily 
pretreated with cytotoxic chemotherapies prior to study 
enrollment. Nevertheless, it is important to note that 
not all gBRCAm-associated HGSOC patients respond 
to PARPi-based therapy and our assay could be comple-
mentary to guide the PARPi treatment in HR-deficient 
HGSOC with gBRCAm carriers. The exploratory nature 
of our study requires that these findings be examined in 
a prospective and powered setting before definitive con-
clusions can be drawn.
Collection of PBMCs as a surrogate tissue to moni-
tor DNA damage response has several advantages over 
tumor biopsy or circulating tumor cells (CTCs), includ-
ing minimally invasive sample collection, the ability to 
collect multiple samples for longitudinal assessment of 
drug effect, and a reliable yield of a number of cells since 
isolation and enumeration of CTCs are often challenges 
in HGSOC [45, 46]. It has been proposed that the in vitro 
radiosensitivity of PBMCs correlates with individual sen-
sitivity to ionizing radiation in breast cancer patients, and 
the in vitro radiosensitivity of PBMCs is higher in lung, 
head and neck, and breast cancer patients compared to 
healthy donors [18, 47–49]. It is possible that a differ-
ent composition of lymphocyte subpopulation of PBMC 
was collected from cancer patients compared to healthy 
donors, and this difference may not reflect tumor per se. 
Quantification of γH2AX and MRE11 at the single-cell 
level by multiparametric flow cytometry using CTCs or 
tissue samples may be considered as another application.
There are now a number of PARPi in phase I to III clini-
cal investigation in gBRCAm associated- ovarian cancer 
and other solid tumors. There is a need to develop a func-
tional assay to reflect HR potential that is feasible and 
applicable in clinical settings to facilitate individualizing 
therapy. HR deficiency may identify a distinct patient 
population with favorable biologic features for HR-tar-
geted therapy not only in the context of HGSOC but also 
in other cancer types. Our data present an opportunity 
to apply a simple, high-throughput method using easily 
obtainable PBMCs, and our exploratory findings, though 
provocative, require sufficiently powered prospective 
studies.
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Conclusions
Our results demonstrate the successful development and 
application of multiparameter flow cytometry measuring 
γH2AX and MRE11 in PBMCs and support further of 
this assay as a potential predictive biomarker to PARPi-
based therapy.
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